Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...